{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:05:08Z","timestamp":1747181108191,"version":"3.40.5"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","license":[{"start":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:00:00Z","timestamp":1672358400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,30]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>With the increasing aging and the popularization of medical diagnosis, the growing number of oldest old with lung cancer needs to be focused on. Several medical and physiological challenges often accompanying the oldest old cancer patients make the choice of the optimal treatment daunting. The current research suggests that people who get adequate treatment can benefit, but it is worth discussing which treatment will benefit them more. High-dose-rate (HDR) <jats:sup>192<\/jats:sup>Ir brachytherapy deserves attention in this context owing to its association with less trauma and reduced complications.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation:<\/jats:title>\n            <jats:p>An 86-years-old woman with a right glandular lung carcinoma presented with progressive lesions 11 months after chemotherapy. Because of her old age and poor performance status (eastern cooperative oncology group performance status 3), she received HDR <jats:sup>192<\/jats:sup>Ir brachytherapy for her right lung lesion without any common complications, such as pneumothorax and hemorrhage. She continued on 0.25\u2009g oral gefitinib each day after received brachytherapy treatment. The right lung lesion keeps a partial response until 18 months later now.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>HDR <jats:sup>192<\/jats:sup>Ir brachytherapy can potentially be used as a safe and effective choice for the oldest old with advanced non-small cell lung cancer. It can especially benefit cancer patients with concurrent chemotherapy or targeted therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000032450","type":"journal-article","created":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T13:05:28Z","timestamp":1672405528000},"page":"e32450","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Implantation of computed tomography-guided high-dose-rate 192Ir brachytherapy in oldest old patients with advanced non-small cell lung cancer: A case report and literature review"],"prefix":"10.1097","volume":"101","author":[{"given":"Ran","family":"Cui","sequence":"first","affiliation":[{"name":"Department of Oncology, The First People\u2019s Hospital of Neijiang, Neijiang, Sichuan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiu-Lan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First People\u2019s Hospital of Neijiang, Neijiang, Sichuan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7595-7216","authenticated-orcid":false,"given":"Jian","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First People\u2019s Hospital of Neijiang, Neijiang, Sichuan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.2006.10.3085","article-title":"Lung cancer in the elderly.","volume":"25","author":"Gridelli","year":"2007","journal-title":"J Clin Oncol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1470-2045(02)00730-1","article-title":"A case for geriatric oncology.","volume":"3","author":"Repetto","year":"2002","journal-title":"Lancet Oncol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0959-8049(03)00062-5","article-title":"Geriatric oncology: a clinical approach to the older patient with cancer.","volume":"39","author":"Repetto","year":"2003","journal-title":"Eur J Cancer"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.athoracsur.2019.09.027","article-title":"The oldest old: a National Analysis of outcomes for patients 90 years or older with lung Cancer.","volume":"109","author":"Yang","year":"2020","journal-title":"Ann Thorac Surg"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00408-017-0026-1","article-title":"Lung cancer in the oldest old: a nation-wide study in the netherlands.","volume":"195","author":"Schulkes","year":"2017","journal-title":"Lung"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.brachy.2021.06.149","article-title":"Palliative treatment with high-dose-rate endobronchial interventional radiotherapy (Brachytherapy) for lung cancer patients.","volume":"20","author":"Soror","year":"2021","journal-title":"Brachytherapy"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(12)70139-0","article-title":"Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301).","volume":"13","author":"Atagi","year":"2012","journal-title":"Lancet Oncol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1200\/JCO.2007.12.5435","article-title":"Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database.","volume":"25","author":"Owonikoko","year":"2007","journal-title":"J Clin Oncol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3892\/ol.2015.3204","article-title":"Trans\u2011bronchoscopy with implantation of 125I radioactive seeds in patients with pulmonary atelectasis induced by lung cancer.","volume":"10","author":"Lu","year":"2015","journal-title":"Oncol Lett"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1088\/1361-6560\/aa587c","article-title":"Dedicated high dose rate 192Ir brachytherapy radiation fields for in vitro cell exposures at variable source-target cell distances: killing of mammalian cells depends on temporal dose rate fluctuation.","volume":"62","author":"Veigel","year":"2017","journal-title":"Phys Med Biol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1118\/1.3157105","article-title":"Development of a scatter correction technique and its application to HDR multicatheter breast brachytherapy.","volume":"36","author":"Poon","year":"2009","journal-title":"Med Phys"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00066-006-1536-6","article-title":"High-dose-rate brachytherapy for small-sized peripherally located lung cancer.","volume":"182","author":"Imamura","year":"2006","journal-title":"Strahlenther Onkol"},{"key":"R15-20250504","first-page":"228","article-title":"Ergebnisse der endoluminalen high-dose-rate-bestrahlung von zentralen nichtkleinzelligen bronchialkarzinomen.","volume":"169","author":"Schraube","year":"1993","journal-title":"Strahlenther Onkol"},{"key":"R16-20250504","first-page":"554","article-title":"Brachytherapie in der palliativ-behandlung von patienten mit rezidiv eines nicht-kleinzelligen bronchialkarzinoms nach vorausgegangener strahlentherapie.","volume":"171","author":"Micke","year":"1995","journal-title":"Strahlenther Onkol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ijrobp.2009.05.041","article-title":"Treatment of recurrent bronchial carcinoma: the role of high-dose-rate endoluminal brachytherapy.","volume":"77","author":"Hauswald","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"370","DOI":"10.5114\/jcb.2019.87218","article-title":"Hypofractionated 192Ir source stereotactic ablative brachytherapy with coplanar template assistance in the primary treatment of peripheral lung cancer.","volume":"11","author":"Pang","year":"2019","journal-title":"J Contemp Brachyther"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1002\/mp.12435","article-title":"Design and validation of a CT\u2010guided robotic system for lung cancer brachytherapy.","volume":"44","author":"Dou","year":"2017","journal-title":"Med Phys"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.semradonc.2010.01.005","article-title":"Improving radiation conformality in the treatment of non\u2013small-cell lung cancer.","volume":"20","author":"Chang","year":"2010","journal-title":"Semin Radiat Oncol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.radonc.2009.09.005","article-title":"HDR endobronchial brachytherapy (HDRBT) in the management of advanced lung cancer\u2013comparison of two different dose schedules.","volume":"93","author":"Skowronek","year":"2009","journal-title":"Radiother Oncol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.ijrobp.2015.04.019","article-title":"Computed tomography\u2013guided interstitial high-dose-rate brachytherapy in combination with regional positive lymph node intensity-modulated radiation therapy in locally advanced peripheral non\u2013small cell lung cancer: a phase 1 clinical trial.","volume":"92","author":"Xiang","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:26:56Z","timestamp":1746332816000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,30]]},"references-count":21,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032450","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,12,30]]}}}